

Familial Colorectal Cancer Type X in Central Iran: A New Clinicopathologic Description

Mehrdad Zeinalian¹, Mahdi Hadian¹, Morteza Hashemzadeh-Chaleshtori², Rasoul Salehi¹, Mohammad Hassan Emami^{3,4}

¹Department of Genetics and Molecular Biology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

²Cellular and Molecular Research Center, Shahrekord University of Medical Sciences, Shahrekord, Iran

³Poursina Hakim Research Institute, Isfahan, Iran

⁴Department of Internal Medicine, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

Corresponding Author: Mehrdad Zeinalian, Department of Genetics and Molecular Biology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

Phone: 09131098411

Email: zeinalianmehrdad@gmail.com; m.zeinalian@med.mui.ac.ir

Received: 6, Aug, 2016
Accepted: 17, Oct, 2016

ABSTRACT

Background: Familial colorectal cancer type X (FCCX) is a subtype of mismatch repair (MMR)-proficient colorectal cancer in which the patients are clinically at risk for Lynch syndrome (LS), a common hereditary cancer predisposing syndrome. In this study, we described a new clinicopathological feature of the condition in central Iran.

Materials and Methods: We designed a descriptive, retrospective study to screen at-risk colorectal cancer (CRC) patients, using Amsterdam II criteria and Molecular analysis in Isfahan (central Iran) throughout 2000-2013 period.

Results: 219 early-onset (≤ 50 years) CRC patients of 1659 were selected for the evaluation. Amsterdam II criteria were positive in 45 families; of whom 31 were finally analyzed by molecular testing.

MMR deficiency was detected in 7/31 probands (22.6%) as affected to LS, so 24 families (77.4%) were identified as FCCX. The mean age of the probands at diagnosis among FCCX families was 45.3 years (range 24-69) versus 38.0 years (range 31-50) in LS families. The frequency of CRC among FCCX and LS families was calculated 27.9% and 67.5%, respectively. Also, the most frequent extracolonic cancer among both FCCX and LS families was stomach by 25.5% and 30.8%, respectively. Tumor site was proximal to the splenic flexure in 20.8% and 57.1% of index CRC patients in FCCX and LS families, respectively.

Conclusion: Given the relative high frequency of FCCX and its different phenotype among Iranian populations, we need to set up more advanced molecular studies for exploration of unknown molecular pathways leading to tumorigenesis in this class of CRC patients.

Keywords: Familial colorectal cancer type X, Clinicopathologic, Lynch syndrome, Iran

INTRODUCTION

Colorectal cancer (CRC), the second cause of cancer-related mortality throughout the world^{1,3}, presents hereditary pattern in at least 20% of the cases of which about 5% are related to inherited mutations in known cancer-predisposing genes and

the rest has likely linked to unknown genetic changes⁴⁻⁶.

Hereditary nonpolyposis colorectal cancer (HNPCC) is used to describe a familial cluster of CRC with non-polyposis phenotype. At first, the Amsterdam criteria (AC) were introduced to screen CRC patients at risk for HNPCC according to a positive family

history with at least three affected family members in two or more generations, and one being a first-degree relative of the other two and at least one individual diagnosed before 50 years of age⁷. The AC1 refers to families with at least three colorectal cancers, while in AC2 Lynch-associated extracolonic cancers containing cancers of endometrium, upper urinary tract, small bowel, stomach, liver, brain, breast, and skin were also included^{8,9}.

The HNPCC families are clinically heterogeneous of which about 4% are linked to Lynch syndrome (LS), which may be negative for AC, <1% are attributed to a Lynch-like syndrome, and 2–4% are defined as familial colorectal cancer type X (FCC-X)^{10,11}. LS is identified by germline mutations in at least one of the mismatch-repair (MMR) genes including: MLH1, MSH2, MSH6, and PMS2, however, just about one-third of the LS families fulfill the AC criteria¹²⁻¹⁵. Although, Lynch-like syndrome (LLS) clinically demonstrates AC and tumors with functional MMR gene defects according to immunohistochemical staining and/or microsatellite instability (MSI) testing, no MMR gene mutations are found to justify the disease^{16,18}. FCC-X families are AC positive families with MMR-proficient tumors and no MMR gene mutations^{12,19,20}.

According to recent studies, it seems there is a high frequency of FCC among Iranian populations^{2,9, 21-23}. Meanwhile, no studies have been so far reported to describe clinicopathologic feature of FCC-X among our populations. Accordingly, we try to report a new description of FCC-X families in Central Iran.

MATERIALS AND METHODS

We undertook a descriptive retrospective study to screen FCC patients at risk for LS in Isfahan, Central Province of Iran. Of 1659 CRC patients registered in Poursina Hakim Research Center (PHRC), a referral gastrointestinal cancer center in Isfahan Province, during a 14-year period (2000-2013), at first all patients aged ≤ 50 years were included in our study as the early-onset patients. Then, all CRC patients with Amsterdam II criteria and their families were invited for genetic counseling through which the participants were interviewed about cancer-related family history at-least up to three generations.

Amsterdam II criteria for primary clinical screening in our study included: having at least 3 affected members with one of the HNPCC-associated cancers (CRC, other GI cancers, endometrial, renal, breast (according to some resources), brain, skin, and pelvic cancers) in at least two successive generations, and being one of these three members a first-degree relative of the other two and at least one diagnosed before the age of 50 years.

The drawn pedigrees were reconfirmed by at-least two other members of every family. Besides, the cancer pathologic reports related to all affected family members were possibly requested to confirm the diagnosis, if available. Then, all resected tumors related to the index CRC patients were analyzed molecularly by both MSI testing and Immunohistochemistry (IHC) to detect probable MMR deficiency.

To detect MSI, a commercial pentaplex panel from Promega (MSI Analysis System, Version 1.2) including five mononucleotide markers (BAT-25, BAT-26, MON0-27, NR-21, and NR-24) was used, and two pentanucleotide markers (PentaC and Penta D) were used as indicators to detect specimen mix-ups. We considered tumors as MSI-High (MSI-H) if at least two of five quasi mononucleotide markers showed instability and MSI-Low (MSI-L) if only one marker was unstable.

For IHC, we used a formalin-fixed paraffin-embedded (FFPE) tissue block for each case, including both tumoral and adjacent healthy mucosa. After providing at least a proper section for each protein, we treated the slides with primary antibodies related to MMR proteins according to IHC guideline specific for each immunologic product. The properties of the antibodies were as following: MSH2 (Leica Biosystems: Novocastra, UK, Lyophilized, Product Code (PC): NCL-MSH2) at 1/80 dilution, MLH1 (Leica Biosystems: Novocastra, UK, Liquid, PC: NCL-L-MLH1) at 1/100 dilution, MSH6 (Leica Biosystems: Novocastra, UK, Liquid, PC: NCL-L-MSH6) at 1/100 dilution, and PMS2 (Leica Biosystems: Novocastra, UK, Liquid, PC: NCL-L-PMS2) at 1/100 dilution. Then, the slides were incubated with Post Primary Block reagent and DAB working solution for some minutes, respectively. If the MMR protein has been expressed, the nuclear staining will be present. MMR deficiency leads to

absent nuclear staining in tumor section compared to normal adjacent tissue.

Data were analyzed using SPSS statistics software (Ver.19).

Ethical approval

Ethical approval was received from the Medical Ethics Committee of Shahrekord University of Medical Sciences (Research project Number: 003). The research was carried out according to principles set out in the Declaration of Helsinki 1964 and all subsequent revisions. Informed consent was obtained, and the privacy and confidentiality were observed throughout the study.

RESULTS

We finally identified that 413/1659 (24.9%) CRC patients registered in PHRC throughout 2000-2013 period were affected by early-onset (age ≤ 50 years at diagnosis) CRC. Family history was positive in 72 / 219 patients responding probands (32.9%) and among whom we found finally 53 families (24.2%) with at least three members affected by any type of Lynch-associated cancer according to Amsterdam II criteria. We classified them as “Familial Colorectal Cancer” (FCC) families. Using Amsterdam II criteria,

45/53FCC families were clinically identified as HNPCC families and were considered candidates for molecular testing. The 14 probands were excluded due to lack of their tumor tissues or being unwilling to incorporate.

After both MSI testing and IHC-MMRs, 7 index CRC patients were identified as MMR-deficient group (22.6%), while no MMR deficiency was finally detected among the rest of 24 probands and they were classified as “FCC-X” patients (77.4%).

Mean age at diagnosis in MMR-deficient probands was 38.0 years (range 31-50) versus 45.3 years (range 24-50) (P value < 0.05) among FCC-X probands.

Among MMR-deficient probands, altogether, 57.2% of tumors were located in right colon (including cecum, ascending colon, and transverse colon), while among FCC-X probands 20.8% of tumors were located in right colon.

History of cancer was found in 186 members within 31 HNPCC families. Of whom, 140 cancer patients were related to 24 FCC-X families (5.8 patients per family) and 46 cancer patients were belonged to 7 MMR-deficient families (6.6 patients per family) (Figures 1, 2).




Figure 1: A large pedigree with at least 15 affected members with 6 different cancers. Note that the age onset of cancer is being earlier in recent generation




Figure 2: A large pedigree with at least 10 affected members with 5 different cancers. Note that the age onset of cancer is being earlier in recent generation

Age at diagnosis of cancer was averagely 51.7 and 51.0 among FCC-X families and MMR-deficient families, respectively (P-value = 0.817). Colorectal, stomach, and hematopoietic system with 67.4, 8.7, and 6.5 percent, respectively were most frequent cancers among MMR-deficient families, while among FCC-X families, colorectal, stomach and lung with 39.3, 10.0, and 8.6 percent, respectively, were most frequent cancers (Table 1).

Table 1: Cancer sites among Iranian families with familial colorectal cancers in both FCC-X and MMR deficient subsets

Cancer site	FCC-X families		MMR deficient families		Sum
	Frequency	Percent	Frequency	Percent	
Colorectal	55	39.3	31	67.4	86
Stomach	14	10.0	4	8.7	18
Lung	12	8.6	2	4.3	14
Breast	11	7.9	1	2.2	12
Brain	9	6.4	0	0.0	9
Hepatobiliary tract	7	5.0	2	4.3	9
Intestine	6	4.3	0	0.0	6
Prostate	4	2.9	2	4.3	6
Uterus	4	2.9	1	2.2	5
Skin	3	2.1	0	0.0	3
Hematopoietic system	3	2.1	3	6.5	6
Bladder	3	2.1	0	0.0	3
Thyroid	2	1.4	0	0.0	2
Testis	2	1.4	0	0.0	2
Bone	2	1.4	0	0.0	2
Kidney	1	0.7	0	0.0	1
Pancreas	1	0.7	0	0.0	1
Nasopharynx	1	0.7	0	0.0	1
Total	140	100	46	100	186

FCC-X: Familial colorectal cancer type X; MMR: Mismatch-repair

Pathologically, 8/24 of FCC-X probands (33.3%) were diagnosed at early stages (I or II pathologic TNM stage). In MMR-deficient probands, however, 1/7 (14.3%) cases were diagnosed at early stages. Moreover, mortality rate among FCC-X probands and MMR-deficient probands was 11/24(45.8%) and 1/7 (14.3%), respectively in our study.

DISCUSSION

This paper is the first description of FCC-X among Iranian patients. Given the absence of any systematic program for screening and early detection of at-risk Iranian families, we tried to set up a new pilot study to explore clinicohistopathologic and epidemiologic features of familial colorectal cancer in central Iran. Accordingly, we applied AC-II to screen CRC patients at risk for Lynch syndrome. More than 74% of our Amsterdam positive probands were MMR-proficient, determining a likely high prevalence of FCC-X among our population. According to different studies, particularly among western countries, averagely 21-73% of CRC patients with clinical AC-I/AC-II criteria represent finally FCC-X^{12,24-26}. Apparently, the frequency of FCC-X among Iranian CRC patients is more than western countries. So, more molecular evaluations are necessary to explore genetic causes

of this common subtype of CRC among our population.

Distinct Clinicopathologic Phenotype

Our FCC-X probands were diagnosed averagely more than 7 years later than MMR-deficient probands. It is similar to other studies around the world, so according to a review article, it was calculated 57.3 years in FCC-X versus 49.7 in Lynch syndrome²⁷⁻³⁰. Moreover, a majority of FCC-X CRC tumors were found in left colon (79.2% vs. 42.8% in MMR-deficient tumors). It has been also presented in many similar studies among other populations according which 70% of FCC-X CRC have been found in left side colon^{12,30-32}.

Although there was no meaningful difference between FCC-X and MMR-deficient families in case of mean age at diagnosis and the average number of cancer patients (rather than probands), extracolonic cancers in FCC-X families included more spectrum than MMR-deficient ones. So, altogether 18 organs were affected in cancer patients among FCC-X families versus 8 organs in MMR-deficient families. This finding is against the results obtained from similar studies among other non-Iranian populations, so according to some of the findings, the risk of extracolonic cancers is increased in Lynch syndrome compared to FCC-X families³³⁻³⁵.

Although a more proportion of FCC-X probands in comparison to MMR-deficient ones was identified in early pathologic stage (33.3% vs. 14.3%), mortality rate of FCC-X probands was calculated higher than MMR-deficient ones (45.8% vs.14.3%). It could be due to a relative better survival in MMR-deficient CRC patients in comparison to FCC-X CRC patients, an issue for which there is much evidence in worldwide studies^{12,34-37}.

Distinct clinical phenotype of FCC-X tumors in comparison to MMR-deficient ones is suggestive of a different molecular basis for this common subtype of CRC about which more evaluations are necessary. It also proposes a different protocol for screening and early detection of cancer among FCC-X families. Therefore, given the high frequency of FCC-X among Iranian population, setting up a native screening program according to different properties of all CRC subtypes must be considered.

CONCLUSION

Although there is not enough data about clinical, molecular, and histopathological features of familial

colorectal cancer among Iranian populations, apparently FCC-X subset of this group of cancers is more frequent in our population. Distinct clinical and histopathological phenotype of FCC-X is suggestive of new molecular mechanisms. It also underscores the necessity of revision in guidelines for screening and early-detection of cancer among FCC-X families.

ACKNOWLEDGMENT

We appreciate the helpful cooperation of all health workers in Department of Genetics and Molecular Biology of Isfahan University of Medical Sciences, Poursina Hakim Research Institute, and Cellular and Molecular Research Center of Shahrekord University of Medical Sciences.

REFERENCES

- Haggard FA, Boushey RP. Colorectal cancer epidemiology: incidence, mortality, survival, and risk factors. *Clin Colon Rectal Surg.* 2009;22(4):191.
- Rezaianzadeh A, Safarpour AR, Marzban M, et al. A Systematic Review Over the Incidence of Colorectal Cancer in Iran. *Ann Colorectal Res.* 2015;3(1):e25724.
- Khorrami S, Zavaran Hosseini A, Mowla SJ, et al. Verification of ALDH Activity as a Biomarker in Colon Cancer Stem Cells-Derived HT-29 Cell Line. *Iran J Cancer Prev.* 2015;8(5):e3446.
- Balmaña J, Castells A, Cervantes A. Familial colorectal cancer risk: ESMO Clinical Practice Guidelines. *Ann Oncol.* 2010; 21 Suppl 5:v78-81.
- Patel SG, Ahnen DJ. Familial colon cancer syndromes: an update of a rapidly evolving field. *Curr Gastroenterol Rep.* 2012;14:428-38.
- Woods M, Younghusband H, Parfrey P, et al. The genetic basis of colorectal cancer in a population-based incident cohort with a high rate of familial disease. *Gut.* 2010; 59(10):1369-77
- Vasen HF, Watson P, Mecklin JP, et al. New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC. *Gastroenterology.* 1999;116(6):1453-6.
- Lynch HT, de la Chapelle A. Hereditary colorectal cancer. *N Engl J Med.* 2003;348(10):919-32.
- Zeinalian M, Hashemzadeh-Chaleshtori M, Akbarpour MJ, et al. Epidemioclinical Feature of Early-Onset Colorectal Cancer at-Risk for Lynch Syndrome in Central Iran. *Asian Pac J Cancer Prev.* 2015;16(11):4647-52.
- Rohlin A. Hereditary Colorectal Cancer; Identification, Characterization and Classification of Mutations. Doctoral thesis: University of Gothenburg. Sahlgrenska Academy. Institute of Biomedicine. Department of Medical Genetics. 2015.
- Kastrinos F, Stoffel EM. History, genetics, and strategies for cancer prevention in Lynch syndrome. *Clin Gastroenterol Hepatol.* 2014;12(5):715-27.

12. Dominguez-Valentin M, Therkildsen C, Da Silva S, et al. Familial colorectal cancer type X: genetic profiles and phenotypic features. *Mod Pathol*. 2015;28(1):30-6.
13. Lynch HT, Lynch PM, Lanspa SJ, et al. Review of the Lynch syndrome: history, molecular genetics, screening, differential diagnosis, and medicolegal ramifications. *Clin Genet*. 2009;76(1):1-18.
14. Boland CR, Koi M, Chang DK, et al. The biochemical basis of microsatellite instability and abnormal immunohistochemistry and clinical behavior in Lynch syndrome: from bench to bedside. *Fam Cancer*. 2008;7(1):41-52.
15. Zeinalian M, Emami MH, Naimi A, et al. Immunohistochemical analysis of mismatch repair proteins in Iranian colorectal cancer patients at risk for lynch syndrome. *Iran J Cancer Prev*. 2015;8(1):11-7.
16. Castillejo A, Vargas G, Castillejo MI, et al. Prevalence of germline MUTYH mutations among Lynch-like syndrome patients. *Eur J Cancer*. 2014;50(13):2241-50.
17. Carethers JM. Differentiating Lynch-like from Lynch syndrome. *Gastroenterology*. 2014;146(3):602-4.
18. Kang SY, Park CK, Chang DK, et al. Lynch-like syndrome: characterization and comparison with EPCAM deletion carriers. *Int J Cancer*. 2015;136(7):1568-78.
19. Shiovitz S, Copeland WK, Passarelli MN, et al. Characterisation of familial colorectal cancer Type X, Lynch syndrome, and non-familial colorectal cancer. *Br J Cancer*. 2014;111(3):598-602.
20. Yamaguchi T, Furukawa Y, Nakamura Y, et al. Comparison of clinical features between suspected familial colorectal cancer type X and Lynch syndrome in Japanese patients with colorectal cancer: a cross-sectional study conducted by the Japanese Society for Cancer of the Colon and Rectum. *Jpn J Clin Oncol*. 2015;45(2): 153-9.
21. Mahdavinia M, Bishehsari F, Ansari R, et al. Family history of colorectal cancer in Iran. *BMC cancer*. 2005;5:112.
22. Dolatkah R, Somi MH, Bonyadi MJ, et al. Colorectal Cancer in Iran: Molecular Epidemiology and Screening Strategies. *J Cancer Epidemiol*. 2015;2015:643020
23. Fatemi SR, Pourhoseingholi MA, Asadi F, et al. Recurrence and Five -Year Survival in Colorectal Cancer Patients After Surgery. *Iran J Cancer Prev*. 2015;8(4):e3439.
24. Moreira L, Balaguer F, Lindor N, et al. Identification of Lynch syndrome among patients with colorectal cancer. *Jama*. 2012;308(15):1555-65.
25. Nieminen TT, Abdel-Rahman WM, Ristimäki A, et al. BMPR1A mutations in hereditary nonpolyposis colorectal cancer without mismatch repair deficiency. *Gastroenterology*. 2011;141(1):e23-e6.
26. Peltomäki P, Gao X, Mecklin J-P. Genotype and phenotype in hereditary nonpolyposis colon cancer: a study of families with different vs. shared predisposing mutations. *Fam cancer*. 2001;1(1):9-15.
27. Boland CR, Goel A. Microsatellite instability in colorectal cancer. *Gastroenterology*. 2010;138(6):2073-87. e3.
28. de la Chapelle A, Hampel H. Clinical relevance of microsatellite instability in colorectal cancer. *J Clin Oncol*. 2010;28(20):3380-7.
29. Jenkins MA, Southey MC, Giles GG, et al. Rationale for, and approach to, studying modifiers of risk in persons with a genetic predisposition to colorectal cancer. *Curr Oncol Rep*. 2007;9(3):202-7.
30. Lindor NM. Familial colorectal cancer type X: the other half of hereditary nonpolyposis colon cancer syndrome. *Surg Oncol Clin N Am*. 2009;18(4):637-45.
31. Francisco I, Albuquerque C, Lage P, et al. Familial colorectal cancer type X syndrome: two distinct molecular entities? *Fam cancer*. 2011;10(4):623-31.
32. Lindor NM. Familial colorectal cancer type X: the other half of hereditary nonpolyposis colon cancer syndrome. *Surg Oncol Clin N Am*. 2009;18(4):637-45.
33. Lindor NM, Rabe K, Petersen GM, et al. Lower cancer incidence in Amsterdam-I criteria families without mismatch repair deficiency: familial colorectal cancer type X. *Jama*. 2005;293(16):1979-85.
34. Lynch HT, Lynch JF, Attard TA. Diagnosis and management of hereditary colorectal cancer syndromes: Lynch syndrome as a model. *CMAJ*. 2009;181(5):273-80.
35. Mueller-Koch Y, Vogelsang H, Kopp R, et al. Hereditary non-polyposis colorectal cancer: clinical and molecular evidence for a new entity of hereditary colorectal cancer. *Gut*. 2005;54(12):1733-40.
36. Zeinalian M, Emami MH, Salehi R, et al. Molecular Analysis of Iranian Colorectal Cancer Patients at Risk for Lynch Syndrome: a New Molecular, Clinicopathological Feature. *J Gastrointest Cancer*. 2015;46(2):118-25.
37. Sehgal R, Sheahan K, O'Connell PR, et al. Lynch syndrome: an updated review. *Genes*. 2014;5(3):497-507.